{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:30:13Z","timestamp":1782815413479,"version":"3.54.5"},"reference-count":33,"publisher":"Informa UK Limited","issue":"4-6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Patent Analyst"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1080\/20468954.2025.2535939","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T06:21:07Z","timestamp":1753251667000},"page":"169-173","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Trivalent bispecific anti-MSLN\n            <sub>2<\/sub>\n            \/CD3 antibody for cancer treatment"],"prefix":"10.1080","volume":"13","author":[{"given":"Jorge Antonio Perez","family":"Salda\u00f1a","sequence":"first","affiliation":[{"name":"Universidad Aut\u00f3noma de Guerrero","place":["Chilpancingo, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donaciano","family":"Flores-Robles","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Guerrero","place":["Chilpancingo, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Celestino","family":"Montes","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Guerrero","place":["Chilpancingo, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Mill\u00e1n-Vega","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Guerrero","place":["Chilpancingo, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Sierra-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Guerrero","place":["Chilpancingo, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Perez-Santos","sequence":"additional","affiliation":[{"name":"Benemerita Autonomous University of Puebla","place":["Puebla, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0078"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0507"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0782-5"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13752"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4338"},{"key":"e_1_3_6_9_1","first-page":"119","article-title":"Portrazza. Necitumumab, an IgG1 monoclonal antibody, FDA approved for advanced squamous non-small-cell lung cancer","volume":"9","author":"Fala L","year":"2016","unstructured":"Fala L. Portrazza. Necitumumab, an IgG1 monoclonal antibody, FDA approved for advanced squamous non-small-cell lung cancer. Am Health Drug Benefits. 2016;9(Spec Feature):119\u2013122.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-6-713"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0221"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae151"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1655"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032759"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365513.2023.2168213"},{"key":"e_1_3_6_16_1","unstructured":"Ebel W Grasso L Nicolaides NC et al. Anti-Mesothelin Antibodies. United States patent US2006204506. 2006 Sep 14."},{"key":"e_1_3_6_17_1","unstructured":"Dimitrov DS Feng Y Pastan IH. The government of the United States of America USA. Human anti-mesothelin monoclonal antibodies. United States patent US2011020361. 2011 Jan 27."},{"key":"e_1_3_6_18_1","unstructured":"Ho M Pastan IH Dimitrov DS et al. US health. Mesothelin antibodies and methods for eliciting potent antitumor activity. United States patent US2015274836. 2015 Jan 10."},{"key":"e_1_3_6_19_1","unstructured":"Kahnert A Light D Schneider D et al. Bayer Schering Pharma. Anti-mesothelin antibodies and uses thereof. United States patent US2011027268. 2011 Feb 3."},{"key":"e_1_3_6_20_1","unstructured":"Zhong Z Ye F Siegel M et al. ANWITA biosciences USA. Anti-mesothelin constructs and uses thereof. United States patent US2021340272. 2021 Nov 4."},{"key":"e_1_3_6_21_1","unstructured":"Terrett JS Pogue SL Toy K et al. Bristol Myers and Squibb USA. Human antibodies that bind mesothelin and uses thereof. United States patent US2011262448. 2011 Oct 27."},{"key":"e_1_3_6_22_1","unstructured":"Kahnert A Berhorster K Heisler I et al. Bayer IP Germany. Anti-mesothelin immunoconjugates and uses thereof. United States patent US2015322160. 2025 Nov 12."},{"key":"e_1_3_6_23_1","unstructured":"Stevens B Baum PR Dubose R et al. Silverback therapeutics USA. Anti-mesothelin antibodies and immunoconjugates thereof. United States patent US2022249685. 2022 Aug 11."},{"key":"e_1_3_6_24_1","unstructured":"Mu\u00f1oz-Olaya J Tuna M Fertin R et al. F STAR DELTA USA. Mesothelin and CD137 binding molecules. United States patent US2021309753. 2021 Oct 7."},{"key":"e_1_3_6_25_1","unstructured":"Fanslow WCH III Kozlosky C Gudas JM et al. Anti-mesothelin binding proteins. United States patent US2014004121. 2014 Jan 2."},{"key":"e_1_3_6_26_1","unstructured":"Desjarlais JR Moore G Hedvat M et al. Xencor USA. Anti-CD28 X anti-MSLN antibodies. United States patent US2023340128. 2023 Oct 26."},{"key":"e_1_3_6_27_1","unstructured":"Zhu J Huang H Song Z et al. Jecho Laboratories. Anti-mesothelin bispecific antibodies and methods of use. Worldwide patent WO2024119065. 2024 Jun 6."},{"key":"e_1_3_6_28_1","unstructured":"Wesche H Lemon BD Austin RJ et al. Harpoon Therapeutics USA. MSLN targeting trispecific proteins and method of use. United States patent US2018327508. 2018 Nov 15."},{"key":"e_1_3_6_29_1","unstructured":"Lim Y Sh L Won A et al. Green Groos Korea. Fusion protein comprising anti-mesothelin antibody anti-CD3 antibody or anti-EGFR antibody bispecific or trispecific antibody comprising same and uses thereof. United States patent US2022251176. 2022 Aug 11."},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3392"},{"key":"e_1_3_6_31_1","unstructured":"Afacan N Ch P Spreter VK et al. Zymeworks BC USA. Multivalent and bispecific antibody constructs and methods of use thereof. Worldwide patent WO2024020703. 2024 Feb 1."},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01482-w"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.81494"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2034355"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016243"}],"container-title":["Pharmaceutical Patent Analyst"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20468954.2025.2535939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T14:22:21Z","timestamp":1755613341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/20468954.2025.2535939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":33,"journal-issue":{"issue":"4-6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1080\/20468954.2025.2535939"],"URL":"https:\/\/doi.org\/10.1080\/20468954.2025.2535939","relation":{},"ISSN":["2046-8954","2046-8962"],"issn-type":[{"value":"2046-8954","type":"print"},{"value":"2046-8962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippa20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippa20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}